Gravity Analytica

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

STOK 01.08.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-15

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our STOK Tweets

About Gravity Analytica

Recent Filings

BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 8, 2025--Stoke Therapeutics, Inc.(Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the 43rd AnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 15, 2025, at6:00 p.m. ET(3:00 p.m. PT).

A live audio webcast of the presentation will be available on the Investors & News section of Stoke’s website athttps://investor.stoketherapeutics.com/and can be accessed by following thisLink. A replay of the webcast will be available for 30 days following the presentation.

AboutStoke Therapeutics

Stoke Therapeutics(Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered inBedford, Massachusettswith offices inCambridge, Massachusetts. For more information, visithttps://www.stoketherapeutics.com/.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250108980972/en/

Stoke Media & Investor Contacts:Dawn KalmarChief Communications Officerdkalmar@stoketherapeutics.com781-383-8417

Doug SnowDirector, Communications & Investor RelationsIR@stoketherapeutics.com508-642-6485

Source:Stoke Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com